Role of botulinum toxin in migraine therapy

Drug Development Research

Volumn 68, Issue 7, 2007, Pages 397-402

  Schulte Mattler, Wilhelm J ^a   Leinisch, Elke ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Botulinum toxin; Headache; Migraine; Pain

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN; BOTULINUM TOXIN A; NEUROPEPTIDE; PLACEBO;

CHRONIC DAILY HEADACHE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; HUMAN; INJECTION SITE; MIGRAINE; MUSCLE CONTRACTION; NOCICEPTION; PATHOPHYSIOLOGY; REVIEW;

EID: 38849088129     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20206     Document Type: Review

References (50)

1. 2004. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 24(Suppl 1):9-160.
2. Altman DG. 1991. Practical statistics for medical research. London: Chapman & Hall.
3. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K. 2001. Botulinum toxin as a biological weapon: medical and public health management. JAMA 285:1059-1070.
4. Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM. 2007. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 47:486-499.
5. Barrientos N, Chana P. 2003. Botulinum toxin type A in prophylactic treatment of migraine headaches: a preliminary study. J Headache Pain 4:146-151.
6. Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P, Sudhof TC, Niemann H, Jahn R. 1993. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 365:160-163.
7. Blersch W, Schulte-Mattler WJ, Przywara S, May A, Bigalke H, Wohlfarth K. 2002. Botulinum, toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci 205:59-63.
8. Blumenfeld A. 2004. Botulinum toxin type A for the treatment of headache: pro. Headache 44:825-830.
9. Blumenfeld AM, Binder W, Silberstein SD, Blitzer A. 2003. Procedures for administering botulinum toxin type A for migraine and tension-type headache. Headache 43:884-891.
10. Brin MF, Fahn S, Moskowitz C, Friedman A, Shale HM, Greene PE, Blitzer A, List T, Lange D, Lovelace RE, McMahon D. 1987. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 2:237-254.
11. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. 2000. An association between migraine and cutaneous allodynia. Ann Neurol 47:614-624.
12. Cui M, Khanijou S, Rubino J, Aoki KR. 2004. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107:125-133.
13. Diener HC. 2003. RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Cephalalgia 23:183-185.
14. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER. 2006. SV2 is the protein receptor for botulinum neurotoxin A. Science 312:592-596.
15. Durham PL, Cady R, Cady R. 2004. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44:35-42.
16. Edvinsson L. 2001. Sensory nerves in man and their role in primary headaches. Cephalalgia 21:761-764.
17. Elkind AH, O'Carroll P, Blumenfeld A, DeGryse R, Dimitrova R. 2006. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain 7:688-696.
18. Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A. 2004. Botulinum toxin A in the prophylactic treatment of migraine - a randomized, double-blind, placebo-controlled study. Cephalalgia 24:838-843.
19. Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L. 2006. The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 122:315-325.
20. Gill MD. 1982. Bacterial toxins: a table of lethal amounts. Microbiol Rev 46:86-94.
21. Goadsby PJ, Edvinsson L, Ekman R. 1990. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28:183-187.
22. Hallett M. 1999. One man's poison - clinical applications of botulinum toxin. N Engl J Med 341:118-120.
23. Ishikawa H, Mitsui Y, Yoshitomi T, Mashimo K, Aoki S, Mukuno K, Shimizu K. 2000. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol 44:106-109.
24. Jakubowski M, McAllister PJ, Bajwa ZH, Ward TN, Smith P, Burstein R. 2006. Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A. Pain 125:286-295.
25. Kramer HH, Angerer C, Erbguth F, Schmelz M, Birklein F. 2003. Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol 250:188-193.
26. Lee WS, Moussaoui SM, Moskowitz MA. 1994. Blockade by oral or parenteral RPR 100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea-pig dura mater and conjunctiva. Br J Pharmacol 112:920-924.
27. Mahrhold S, Rummel A, Bigalke H, Davletov B, Binz T. 2006. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett 580:2011-2014.
28. Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G, Pacchetti C. 2003. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 18:685-688.
29. Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C. 2005. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 45:293-307.
30. Moskowitz MA. 1990. Basic mechanisms in vascular headache. Neurol Clin 8:801-815.
31. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM. 2004. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104-1110.
32. Ondo WG, Vuong KD, Derman HS. 2004. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia 24:60-65.
33. Phebus LA, Johnson KW, Stengel PW, Lobb KL, Nixon JA, Hipskind PA. 1997. The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs. Life Sci 60:1553-1561.
34. Rapp DE, Turk KW, Bales GT, Cook SP. 2006. Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 175(Pt 1):1138-1142.
35. Relja M, Poole AC, Schoenen J, Pascual J, Lei X, Thompson C. 2007. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 27:492-503.
36. Rosales RL, Bigalke H, Dressler D. 2006. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol 13(Suppl 1):2-10.
37. Schiavo G, Matteoli M, Montecucco C. 2000. Neurotoxins affecting neuroexocytosis. Physiol Rev 80:717-766.
38. Schnider P, Binder M, Auff E, Kittler H, Berger T, Wolff K. 1997. Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. Br J Dermatol 136:548-552.
39. Schulte-Mattler WJ, Krack P. 2004. Treatment of chronic tension-type headache with hotulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain 109:110-114.
40. Schulte-Mattler WJ, Opatz O, Blersch W, May A, Bigalke H, Wohlfahrt K. 2007. Botulinum toxin A does not alter capsaicin-induced pain perception in human skin. J Neurol Sci 260:38-42.
41. Silberstein S, Mathew N, Saper J, Jenkins S. 2000. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 40:445-450.
42. Silberstein SD, Stark SR, Lucas SM, Christie SN, Degryse RE, Turkel CC. 2005. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 80:1126-1137.
43. Sycha T, Samal D, Chizh B, Lehr S, Gustorff B, Schnider P, Auff E. 2006. A lack of antinociceptive or antiinflammatory effect of botulinum toxin a in an inflammatory human pain model. Anesth Analg 102:509-516.
44. Tfelt-Hansen P, Block G, Dahlof C, Diener HC, Ferrari MD, Goadsby PJ, Guidetti V, Jones B, Lipton RB, Massiou H, Meinert C, Sandrini G, Steiner T, Winter TB. 2000. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 20:765-786.
45. Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB. 1986. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 2:245-247.
46. Voller B, Sycha T, Gustorff B, Schmetterer L, Lehr S, Eichler HG, Auff E, Schnider P. 2003. A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology 61:940-944.
47. Welch KM. 2004. Botulinum toxin type A for the treatment of headache: con. Headache 44:831-833.
48. Welch MJ, Purkiss JR, Foster KA. 2000. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38:245-258.
49. Wohlfarth K, Goschel H, Frevert J, Dengler R, Bigalke H. 1997. Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol 355:335-340.
50. Yokosawa N, Suga K, Kimura K, Tsuzuki K, Fujii N, Oguma K, Yokosawa H. 1994. Exogenous zinc ion is required for inhibitory activity of botulinum neurotoxin C1 against norepinephrine release and its endopeptidase activity toward substance P. Biochem Mol Biol Int 32:455-463.